Jespride M 1mg/500mg Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 500mg in a sustained-release formulation. It is primarily indicated for the management of type 2 diabetes mellitus, particularly in patients whose blood glucose levels are inadequately controlled by diet and exercise alone. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The sustained-release formulation allows for a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Jespride M is typically administered once daily with meals to optimize absorption and minimize adverse effects. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in conditions such as diabetic ketoacidosis and severe renal dysfunction. This combination therapy offers a synergistic approach to glycemic control, improving patient compliance through reduced pill burden.